Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CASI Pharmaceuticals, Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 125 staff and has a trailing 12-month revenue of around USD$11.7 million.
|Latest market close||USD$2.78|
|52-week range||USD$1.3401 - USD$3.32|
|50-day moving average||USD$2.3948|
|200-day moving average||USD$2.0559|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.444|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-6.71%|
|1 month (2020-12-18)||2.78|
|3 months (2020-10-16)||68.48%|
|6 months (2020-07-17)||22.47%|
|1 year (2020-01-17)||-13.13%|
|2 years (2019-01-18)||-23.63%|
|3 years (2018-01-18)||3.98|
|5 years (2016-01-15)||286.11%|
|Revenue TTM||USD$11.7 million|
|Gross profit TTM||USD$196,000|
|Return on assets TTM||-17.67%|
|Return on equity TTM||-42.85%|
|Market capitalisation||USD$363.2 million|
TTM: trailing 12 months
There are currently 1.9 million CASI Pharmaceuticals shares held short by investors – that's known as CASI Pharmaceuticals's "short interest". This figure is 1.5% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting CASI Pharmaceuticals shares can be evaluated.
CASI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CASI Pharmaceuticals shares currently shorted divided by the average quantity of CASI Pharmaceuticals shares traded daily (recently around 411580.39215686). CASI Pharmaceuticals's SIR currently stands at 4.59. In other words for every 100,000 CASI Pharmaceuticals shares traded daily on the market, roughly 4590 shares are currently held short.
However CASI Pharmaceuticals's short interest can also be evaluated against the total number of CASI Pharmaceuticals shares, or, against the total number of tradable CASI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CASI Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CASI Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0219% of the tradable shares (for every 100,000 tradable CASI Pharmaceuticals shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CASI Pharmaceuticals.
Find out more about how you can short CASI Pharmaceuticals stock.
We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.
CASI Pharmaceuticals's shares were split on a 1:11 basis on 1 July 2010. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.
Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.3401 up to $3.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.4205. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.